Entrada Therapeutics Inc. Common Stock (TRDA)

About TRDA

Entrada Therapeutics, Inc., is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle, therapeutic candidates are based on a novel therapeutic; a robust development portfolio of genetic medicines for the potential treatment of neur…

Sector

Health Care

Industry

Biotechnology: Pharmaceutical Preparations

Employees

152

Website

www.entradatx.com/

Fundamentals

1-day range

$6.8$7.37

Market cap

$266.70M

P/E (trailing)

—

P/E (forward)

-2.32

EPS (trailing)

$-3.97

Dividend yield

—

Beta

-0.28

Avg. volume

348.7K

Forecasts

4 analyst ratings

Entrada Therapeutics Inc. Common Stock Competitors

Chosen by industry and closest market cap.

• TRDA

  Entrada Therapeutics Inc. Common Stock

  $7

  ▼ 3.71%
  Market cap $266.70MP/E —
  $5.02$16.45
• ELDN

  Eledon Pharmaceuticals Inc. Common Stock

  $3.19

  ▼ 3.92%
  Market cap $267.07MP/E —
  $1.35$4.6
• VRXA

  Veraxa Biotech AG Ordinary Shares

  $1.36

  ▼ 5.56%
  Market cap $263.02MP/E —
  $1.32$27.36
• EBS

  Emergent BioSolutions Inc. Common Stock

  $5.91

  ▼ 0.51%
  Market cap $273.98MP/E —
• BCYC

  Bicycle Therapeutics plc American Depositary Shares

  $4.21

  ▼ 2.77%
  Market cap $277.87MP/E —
  $3.75$9.16
• MGNX

  MacroGenics Inc. Common Stock

  $4.13

  ▲ 1.23%
  Market cap $254.89MP/E —
  $1.29$5.08
• WHWK

  Whitehawk Therapeutics Inc. Common Stock

  $4.65

  ▼ 4.52%
  Market cap $252.78MP/E —
  $1.76$5.5

P/E shows — for peers not currently carrying a live signal of their own.

Institutional Ownership

March 31, 2026

Total shares held

25.08M

Total value held

$305.35M

Institutional holders

114